When a rheumatologist prescribes Humira instead of a biosimilar, or an oncologist insists on Ocrevus over a generic alternative, it’s not because they’re ignoring cost - it’s because they’ve seen what happens when patients switch. In specialty medicine, the choice between brand-name and generic isn’t just about money. It’s about trust, uncertainty, and real-world outcomes that don’t always show up in clinical trials.
What Makes a Drug "Specialty"?
Specialty drugs aren’t just expensive. They’re complex. These medications treat rare, chronic, or life-threatening conditions like multiple sclerosis, rheumatoid arthritis, cancer, and rare genetic disorders. They often require special handling - refrigeration, sterile mixing, or infusion at a clinic. Many are injected or given intravenously. And they’re not something you pick up at your local pharmacy. You need a specialty pharmacy, trained staff, and a care coordinator just to get started.
According to the 2024 Journal of Managed Care & Specialty Pharmacy, specialty drugs make up only 6.2% of all prescriptions filled in the U.S., but they account for 71.1% of total prescription drug spending. That’s staggering. One patient on a specialty drug can cost more than 75 times what a typical patient spends on meds each year. And it’s not slowing down. By 2028, experts predict these drugs will make up 73% of global pharmaceutical spending.
Why Don’t Specialists Just Switch to Cheaper Options?
It’s tempting to think: if a biosimilar costs 30% less, why not use it? But in specialty care, the stakes are higher. These drugs treat conditions where even small changes in response can mean the difference between remission and flare-up - or life and death.
Take multiple sclerosis. Ocrevus (ocrelizumab) and its biosimilars may look identical on paper. But in practice, some patients develop antibodies to the biosimilar version that don’t appear with the brand. A 2023 study in Neurology found that 12% of MS patients who switched from brand to biosimilar experienced a relapse within six months. That’s not a small number - it’s a real risk.
Doctors aren’t ignoring cost. They’re weighing risk. When a patient has spent years stabilizing their disease, a switch isn’t just a substitution - it’s an experiment. And specialists are the ones who have to answer when it goes wrong.
The Role of PBMs and Hidden Markups
Here’s where it gets messy. Pharmacy Benefit Managers (PBMs) like CVS Caremark, Express Scripts, and OptumRx control how these drugs reach patients. They negotiate prices with manufacturers, manage formularies, and operate their own specialty pharmacies. But a January 2025 Federal Trade Commission report revealed something shocking: PBMs were marking up specialty generic drugs by thousands of percent.
For example, a generic drug that costs $100 to acquire might be billed to insurers at $1,500. That’s not a markup - it’s a tax on patients. And it’s happening even when a cheaper alternative exists. Why? Because PBMs profit more when they dispense through their own pharmacies - and they often steer patients there, regardless of cost or preference.
This isn’t about doctors being greedy. It’s about a system that rewards complexity over transparency. When a specialist sees a patient’s copay jump from $50 to $850 overnight because their insurance switched pharmacies, they don’t blame the patient. They blame the system. And sometimes, they keep prescribing the brand name simply because it’s the only way to ensure consistent access.
How Payments Influence Prescribing
It’s no secret that pharmaceutical companies pay doctors. A ProPublica analysis from 2016 found that doctors who received over $5,000 in payments from drug makers prescribed brand-name drugs at a rate 50% higher than those who received nothing. That’s not a coincidence - it’s a pattern.
But it’s not just about kickbacks. It’s about education. Drug companies fund continuing medical education, sponsor conferences, and provide patient support programs. When a specialist gets deep training on a brand-name drug - including how to manage side effects, handle insurance denials, and access financial aid - they’re more likely to stick with it. The alternatives? Often poorly documented, with no support network.
One rheumatologist in Ohio told a Medscape survey respondent: "I’ve tried biosimilars. But when my patient’s pain came back, and their insurance wouldn’t cover the switch back, I had to spend 18 hours on the phone just to get them back on the original drug. I don’t want to do that again. Ever."
The Burden on Providers
Specialists aren’t just doctors. They’re case managers, insurance navigators, and patient advocates. The American Medical Association reports that physicians spend 13.4 hours per week just on prior authorization requests - and 78% of that time is spent on specialty drugs.
Imagine this: A patient needs a new drug. The doctor writes the prescription. Then comes the fax. Then the call. Then the appeal. Then the denial. Then the second appeal. Then the letter from the patient’s employer. Then the pharmacy delay. Then the 10-day wait for a financial aid application to be approved.
It’s exhausting. And when a brand-name drug has a pre-approved pathway - with dedicated support staff, copay cards, and nurse hotlines - it’s easier to prescribe it. Even if it costs more. Because the alternative isn’t just cheaper - it’s chaotic.
Patient Stories: When the System Fails
Reddit threads and patient forums are full of stories like this:
- "My Humira copay went from $50 to $850. My rheumatologist said biosimilars aren’t right for me. But my plan won’t cover the brand unless I appeal. I’ve been on hold for 90 minutes every day for two weeks."
- "I have a rare form of cancer. The only drug that works is Jakafi. The generic doesn’t exist. The brand is $12,000 a month. My insurance covers 90%, but I still pay $1,200. I’m not complaining - I’m alive. But I shouldn’t have to choose between my health and my rent."
These aren’t outliers. They’re symptoms of a broken system. Specialists aren’t choosing brand names because they’re loyal to Big Pharma. They’re choosing them because, in real life, the alternatives often lead to worse outcomes - or worse, delays that cost patients their health.
What’s Changing? What’s Next?
The Inflation Reduction Act of 2022 gave Medicare the power to negotiate prices for high-cost drugs. That’s a big deal. Drugs like Jakafi, Ofev, and Xtandi - all specialty medications - are already on the list for future negotiations. That could bring prices down.
But it won’t fix everything. The FTC’s 2025 report is pushing for new rules to force PBMs to disclose markups. Senator Bernie Sanders introduced the Specialty Drug Price Transparency Act in February 2025. And CMS proposed new rules in March 2026 that could force PBMs to stop hiding the real cost of these drugs.
Meanwhile, the pipeline is full. Over 2,700 new specialty drugs are in development, nearly half targeting rare diseases. That’s hope - but also more pressure on an already strained system.
The Bottom Line
Specialists don’t prefer brand-name drugs because they’re greedy. They prefer them because, in their experience, the alternatives often fail - not because they’re ineffective, but because the system around them is broken.
When a patient’s insurance changes, and their drug gets pulled from formulary, the specialist doesn’t just write a new script. They become a lifeline. They call pharmacies, file appeals, connect patients with aid programs, and sometimes pay for co-pays out of pocket.
Until the system changes - until PBMs stop hiding markups, until generics come with real support, until prior auth takes less than 13 hours a week - specialists will keep prescribing the brand name. Not because they want to. But because, for their patients, it’s the only reliable path to care.